OBJECTIVES: The goal of research was to investigate the cost of DRG based anti-cancer chemotherapies. Costs for investigated chemotherapies have been allocated to oncology centers from the budget of National Heath Fund Administration, based on DRG-reimbursement. METHODS: Cost analysis of chemotherapy protocols has been conducted, from the perspective of National Heath Fund Administration, focusing on cost of medication, hospitalisation and the total expenditure of protocols. RESULTS: The standard process of protocol-expenditure calculation has been identified. The drug related cost has been based on the ex-factory prices of medicines. Expenditures of hospitalisation have been calculated on the days of total length of drug administration and not on term of hospitalisation. Chemotherapies, containing per os anti-cancer medication have been found over-charged. The cost ratio of oral drug and protocol expenses has been found lower than the average of oncology protocols, from 1,75 to 26.9%. Consequetly, the cost of hospitalisaton has been over-represented in these protocolls, although these treatments have reqired less hospitalisation. Using per os chemotherapy protocols has resulted idle capacity in utilization of protocol-expenditures. CONCLUSION: The cost of hospitalisation based on „days of treatment” hasn't reflected correctly the occurrent expenses. Per os chemotherapies alone should have been reimbursed as outpatient care and not involved into DRG based hospital care. The cost of protocols, containing per os and i.v. compounds in combination should have been calculated on a real-cost basis, considering the days of hospitalisation.